[go: up one dir, main page]

LU88559A1 - Sels de peptides comprenant des polyesters à terminaison carboxy - Google Patents

Sels de peptides comprenant des polyesters à terminaison carboxy Download PDF

Info

Publication number
LU88559A1
LU88559A1 LU88559A LU88559A LU88559A1 LU 88559 A1 LU88559 A1 LU 88559A1 LU 88559 A LU88559 A LU 88559A LU 88559 A LU88559 A LU 88559A LU 88559 A1 LU88559 A1 LU 88559A1
Authority
LU
Luxembourg
Prior art keywords
carboxy
peptides
salts
terminated polyesters
polyesters
Prior art date
Application number
LU88559A
Other languages
English (en)
Inventor
Francis Hutchinson
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of LU88559A1 publication Critical patent/LU88559A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
LU88559A 1992-05-28 1994-11-23 Sels de peptides comprenant des polyesters à terminaison carboxy LU88559A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB@@@@A GB9211268D0 (en) 1992-05-28 1992-05-28 Salts of basic peptides with carboxyterminated polyesters
PCT/GB1993/001079 WO1993024150A1 (fr) 1992-05-28 1993-05-25 Sels de peptides comprenant des polyesters a terminaison carboxy

Publications (1)

Publication Number Publication Date
LU88559A1 true LU88559A1 (fr) 1995-04-05

Family

ID=10716132

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88559A LU88559A1 (fr) 1992-05-28 1994-11-23 Sels de peptides comprenant des polyesters à terminaison carboxy

Country Status (33)

Country Link
US (3) US5889110A (fr)
JP (1) JPH08501064A (fr)
KR (1) KR100293882B1 (fr)
AT (1) AT407702B (fr)
AU (1) AU682310B2 (fr)
BE (1) BE1006143A3 (fr)
CA (1) CA2136751C (fr)
CH (2) CH690491A5 (fr)
CZ (1) CZ292449B6 (fr)
DE (2) DE4392401B4 (fr)
DK (1) DK176134B1 (fr)
ES (1) ES2107357B1 (fr)
FI (1) FI112603B (fr)
FR (1) FR2691631B1 (fr)
GB (3) GB9211268D0 (fr)
GR (1) GR1001550B (fr)
HK (1) HK133097A (fr)
HU (1) HUT70177A (fr)
IE (1) IE74715B1 (fr)
IL (1) IL105710A (fr)
IT (1) IT1271139B (fr)
LU (1) LU88559A1 (fr)
MC (1) MC2330A1 (fr)
NL (1) NL195056C (fr)
NO (1) NO311006B1 (fr)
NZ (1) NZ252268A (fr)
RU (1) RU2152225C1 (fr)
SE (1) SE501970C2 (fr)
SG (1) SG44645A1 (fr)
SK (1) SK280320B6 (fr)
TW (1) TW223018B (fr)
WO (1) WO1993024150A1 (fr)
ZA (1) ZA933358B (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
CN1146402C (zh) * 1996-12-20 2004-04-21 阿尔萨公司 凝胶组合物及方法
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
EP1240896A3 (fr) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation de peptides hydrosolubles
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2001093835A1 (fr) * 2000-06-02 2001-12-13 Zycos Inc. Systemes de distribution d'agents bioactifs
WO2002036169A2 (fr) * 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methodes et compositions pour ameliorer l'administration de molecules bioactives
AU2002324447B2 (en) 2001-06-22 2006-06-29 Durect Corporation Zero-order prolonged release coaxial implants
US6873915B2 (en) * 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
AU2002335077B2 (en) * 2001-10-19 2006-09-07 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
KR20040058101A (ko) * 2001-11-14 2004-07-03 알자 코포레이션 카테터 주입가능한 데포 조성물 및 그의 용도
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
ATE374598T1 (de) * 2002-03-15 2007-10-15 Alrise Biosystems Gmbh Mikropartikel und verfahren zur deren herstellung
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
AU2003244157A1 (en) 2002-06-25 2004-01-06 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
AU2002359397B2 (en) * 2002-07-31 2009-01-29 Durect Corporation Injectable depot compositions and uses thereof
BR0313539A (pt) * 2002-07-31 2005-06-21 Alza Corp Composições depósito de polìmero multimodais injetáveis e seus usos
CN104383554B (zh) 2002-09-06 2018-06-08 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
CN1713890A (zh) 2002-11-06 2005-12-28 阿尔萨公司 控释储库制剂
DK1911763T3 (da) 2003-01-28 2010-11-15 Ironwood Pharmaceuticals Inc Sammensætninger til behandling af mavetarmsygdomme
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7741268B2 (en) * 2003-04-02 2010-06-22 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
WO2004112826A1 (fr) * 2003-06-20 2004-12-29 Ares Trading Sa Formulations lyophilisees a base de fsh/lh
EP1660013A4 (fr) 2003-08-26 2011-07-20 Gel Del Technologies Inc Biomateriaux et biocoacervats proteiniques, leurs procedes de fabrication et d'utilisation
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
EP1682537B1 (fr) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulateurs de l'adhesion cellulaire
US8529939B2 (en) 2003-12-08 2013-09-10 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
WO2005074968A2 (fr) * 2004-02-10 2005-08-18 Universiteit Maastricht Utilisation medicale de peptides basiques
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
EP1674082A1 (fr) * 2004-12-22 2006-06-28 Zentaris GmbH Procédé pour la manufacture des suspensions ou lyophilisates steriles des complexes mal-soluble de peptides basic, des formulations pharmaceutiques avec ces complexes et leur utilisation comme medicament
CN102617557A (zh) 2005-05-17 2012-08-01 萨可德生物科学公司 治疗眼病的组合物和方法
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
US8945598B2 (en) * 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
EP1837014A1 (fr) * 2006-03-21 2007-09-26 Hexal Ag Implants sous-cutanés contenant un polymère de polylactide résistant à la dégradation et un analogue de la LH-RH
ITMI20061538A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
EP1917971A1 (fr) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Préparations à libération prolongée comprenant des polymères à poids moléculaire très bas
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (fr) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
US20090163603A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends
WO2009086483A2 (fr) 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Particules de protéines biocompatibles, dispositifs à particules et leurs procédés
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
WO2009149279A2 (fr) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010009319A2 (fr) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010057177A2 (fr) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Systèmes de greffe de vaisseaux à biocoacervats et biomatériaux protéiques et procédés pour leur fabrication et leur utilisation
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
CA2774015A1 (fr) 2009-09-15 2011-03-24 Cerulean Pharma Inc. Conjugue de cdp-camptothecine, composition a distribution des orientations de particules et leurs utilisations
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2434315T3 (es) * 2009-12-22 2013-12-16 Takeda Pharmaceutical Company Limited Formulación de liberación sostenida
DE102010003615A1 (de) 2010-04-01 2011-10-06 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Herstellung eines Drug-Delivery-Systems auf der Basis von Polyelektrolytkomplexen
CA2927832C (fr) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Conjugues d'agent therapeutique polymere renfermant de la cyclodextrine et leur utilisation
EP2585092A1 (fr) 2010-06-24 2013-05-01 Torrent Pharmaceuticals Limited Composition pharmaceutique contenant de la goséréline pour un implant in situ
UY33465A (es) * 2010-06-25 2012-01-31 Takeda Pharmaceutical Formulacion de liberacion sostenida
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
KR101467275B1 (ko) * 2011-12-19 2014-12-02 주식회사 삼양바이오팜 분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
IN2015DN00847A (fr) 2012-07-25 2015-06-12 Sarcode Bioscience Inc
WO2014055493A1 (fr) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Procédés et systèmes s'appliquant à la précipitation de polymères et à la génération de particules
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
ES2804702T3 (es) * 2013-03-04 2021-02-09 Besins Healthcare Lu Sarl Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo unidas a partículas de portador
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
CA2931547A1 (fr) 2013-12-09 2015-06-18 Durect Corporation Complexes de principes pharmaceutiquement actifs, complexes de polymeres, et compositions et procedes les impliquant
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
US12156897B2 (en) 2016-04-12 2024-12-03 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN110954491B (zh) * 2019-12-09 2022-11-15 北京博恩特药业有限公司 用于测量醋酸戈舍瑞林缓释植入剂体外溶出度的方法
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
EP4192509A1 (fr) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Traitement du cancer à l'aide d'un conjugué polymère contenant de la cyclodextrine-inhibiteur de la topoisomérase et d'un inhibiteur de parp
US20250009647A1 (en) 2021-08-05 2025-01-09 Medincell S.A. Pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5005602A (en) * 1985-12-24 1991-04-09 Dover Corporation Poppet valve assembly
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CH679207A5 (fr) * 1989-07-28 1992-01-15 Debiopharm Sa
CA2065156A1 (fr) * 1990-07-03 1992-01-04 Richard L. Dunn Systemes de liberation intragingival pour le traitement d'une maladie periodontique
CA2046830C (fr) * 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

Also Published As

Publication number Publication date
AU4084793A (en) 1993-12-30
IE74715B1 (en) 1997-07-30
NZ252268A (en) 1996-12-20
BE1006143A3 (fr) 1994-05-24
SE9404115L (sv) 1994-11-28
SG44645A1 (en) 1997-12-19
IL105710A0 (en) 1993-09-22
US6034175A (en) 2000-03-07
IL105710A (en) 2001-03-19
NL9320034A (nl) 1995-04-03
MC2330A1 (fr) 1994-05-31
CH690491A5 (de) 2000-09-29
SK280320B6 (sk) 1999-11-08
SE501970C2 (sv) 1995-07-03
DE4392401B4 (de) 2007-05-16
FR2691631B1 (fr) 1995-06-09
HUT70177A (en) 1995-09-28
CZ292449B6 (cs) 2003-09-17
GB9423366D0 (en) 1995-01-25
CA2136751A1 (fr) 1993-12-09
ES2107357A1 (es) 1997-11-16
FI945553A0 (fi) 1994-11-25
TW223018B (en) 1994-05-01
CH688911A5 (de) 1998-05-29
GR1001550B (el) 1994-04-29
IT1271139B (it) 1997-05-27
NL195056C (nl) 2003-07-01
HK133097A (en) 1997-10-24
NO311006B1 (no) 2001-10-01
US5889110A (en) 1999-03-30
RU2152225C1 (ru) 2000-07-10
GB9309645D0 (en) 1993-06-23
NO944535L (no) 1995-01-25
WO1993024150A1 (fr) 1993-12-09
JPH08501064A (ja) 1996-02-06
ATA901993A (de) 2000-10-15
SE9404115D0 (sv) 1994-11-28
GB2282066A (en) 1995-03-29
RU94046097A (ru) 1996-09-20
DK135394A (da) 1994-11-28
IE930358A1 (en) 1993-12-01
NO944535D0 (no) 1994-11-25
FI112603B (fi) 2003-12-31
ITMI931099A1 (it) 1994-11-27
GB2282066B (en) 1996-11-06
DE4392401T1 (de) 1997-07-24
AU682310B2 (en) 1997-10-02
ZA933358B (en) 1994-09-15
AT407702B (de) 2001-05-25
CZ293794A3 (en) 1995-03-15
US20020198315A1 (en) 2002-12-26
ITMI931099A0 (it) 1993-05-27
HU9403371D0 (en) 1995-02-28
FI945553L (fi) 1995-01-25
KR100293882B1 (ko) 2001-09-17
ES2107357B1 (es) 1998-10-16
GB9211268D0 (en) 1992-07-15
SK143494A3 (en) 1995-07-11
CA2136751C (fr) 2006-10-31
FR2691631A1 (fr) 1993-12-03
DK176134B1 (da) 2006-09-18

Similar Documents

Publication Publication Date Title
LU88559A1 (fr) Sels de peptides comprenant des polyesters à terminaison carboxy
ITPD910047A0 (it) Strumento per la legatura di emorroidi o simili
NO943761D0 (no) Oralt administrerbare opioide formuleringer med forlenget effektvarighet
FI960584L (fi) Terapeuttisia peptidijohdannaisia
DE69433571D1 (de) Verkaufsstellensystem
FI940012L (fi) Aryylisulfonamidosubstituoidut hydroksaamihapot
DE69402724D1 (de) Führungsanlage
DE69424096D1 (de) Bildprozessor
DE69419663D1 (de) Multitasking-Prozessorarchitektur
EP0596729A3 (fr) Afficheur d'image virtuelle pour tableau de bord.
DE69406011D1 (de) Geschütztes bild
DE69424086D1 (de) Bildprozessor
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
MX9205378A (es) Procedimiento para la esterificacion de sales de acidos carboxilicos.
ITMI922701A0 (it) Costruzione modulare di navi mercantili
DE69427663D1 (de) Bildprozessor
ITMI913464A0 (it) Procedimento per la neutralizzazione di perfluoropolissialchileni
DE69323688D1 (de) Epitop-Peptide von menschlichem Parvovirus
DE59410412D1 (de) Bislactone
ATA114093A (de) Markierte alpha aminosäuren
KR940022049U (ko) 문자가 표시되는 향
KR950013137U (ko) 각도 변형 칫솔
ITVR930055A0 (it) Struttura di espositore particolarmente per edicole
IT8822479A0 (it) Sale di calcio biodisponibile e relative composizoni farmaceutiche.
ITRM940151A0 (it) Impiego di esteruretani per la riconcia.